Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Doyle, Lex W ^a   Ehrenkranz, Richard A ^b   Halliday, Henry L ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; OXYGEN; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; GLUCOCORTICOID;

ASTHMA; BAYLEY SCALES OF INFANT DEVELOPMENT; BLINDNESS; BRAIN HEMORRHAGE; CEREBRAL PALSY; CHRONIC LUNG DISEASE; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM PERFORATION; DISABILITY; DRUG EFFICACY; DRUG SAFETY; EXTUBATION; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; GLUCOSURIA; HEARING IMPAIRMENT; HOME CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INFANT; INFECTION; INTELLECTUAL IMPAIRMENT; LUNG DYSPLASIA; NECROTIZING ENTEROCOLITIS; NEUROLOGIC EXAMINATION; NEWBORN; NEWBORN MORTALITY; OXYGEN THERAPY; PHYSIOTHERAPY; PNEUMOTHORAX; POSTNATAL CARE; PREMATURITY; PRIORITY JOURNAL; RECURRENT DISEASE; RETROLENTAL FIBROPLASIA; REVIEW; SKULL DISEASE; SPEECH THERAPY; SURVIVOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; WHEEZING; CHRONIC DISEASE; DRUG ADMINISTRATION; INFANT, PREMATURE, DISEASES; LUNG DISEASES; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LUNG DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84926466829     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001145.pub3     Document Type: Review

References (157)

1. Ariagno RL. Personal communication. email 2000.
2. Ariagno RL, Sweeney TE, Baldwin RB, Inguillo D, Martin D. Controlled trial of dexamethasone in preterm infants at risk for bronchopulmonary dysplasia: lung function, clinical course and outcome at three years. Unpublished manuscript supplied by authors 2000.
3. Ariagno RL, Sweeney TJ, Baldwin RB, Inguillo D, Martin D. Dexamethasone effects on lung function and risks in 3 week old ventilatory dependent preterm infants. American Reviews of Respiratory Disease 1987;135:A125.
4. Avery GB, Fletcher AB, Caplan M, Brudno DS. Control trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985;75:106-11.
5. Brozanski BS, Jones JG, Gilmore CH, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birthweight infant. Journal of Pediatrics 1995;126:769-76.
6. Gilmour CH, Sentipal-Walerius JM, Jones JG, Doyle JM, Brozanski BS, Balsan MJ, et al. Pulse dexamethasone does not impair growth and body composition of very low birth weight infants. Journal of the American College of Nutrition 1995;14:455-62.
7. Hofkosh D, Brozanski BS, Edwards MD, et al. One year outcome of infants treated with pulse dexamethasone for prevention of BPD. Pediatric Research 1995;37:259A.
8. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics 1991;88:421-7.
9. Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3 year follow-up. Pediatrics 1995;96:897-906.
10. Jones RA. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13-to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics 2005;116:370-8.
11. Jones RA. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13-to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. Pediatrics 2005;116:379-84.
12. Cummings JJ. Personal communication. email 2002.
13. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. New England Journal of Medicine 1989;320:1505-10.
14. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005;115:681-7.
15. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 2007;119:716-721.
16. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter international randomized controlled trial. Pediatrics 2006;117:75-83.
17. Durand M. Personal communication. email 2012.
18. Durand M, Sardesi S, McEvoy C. Effect of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized controlled trial. Pediatrics 1995;95:584-90.
19. Harkavy KL. Personal communication. email 2002.
20. Harkavy KL, Scanlow JW, Chowdhry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in ventilator-and oxygen-dependent infants. A controlled trial. Journal of Pediatrics 1989;115:979-83.
21. Kari MA, Heinonen KO, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Archives of Disease of Childhood 1993;68:566-9.
22. Kari MA, Raivio KO, Venge P, Hallman M. Dexamethasone treatment of infants at risk of chronic lung disease: surfactant components and inflammatory parameters in airway specimens. Pediatric Research 1994;36:387-93.
23. Mieskonen S, Eronen M, Malmberg LP, Turpeinen M, Kari MA, Hallman M. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth. Acta Paediatrica 2003;92:896-904.
24. Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics 1990;86:722-7.
25. Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 1996;97:818-21.
26. Goldstein DJ, Waldrep EL, VanPelt JC, O'Shea TM. Developmental outcome at 5 years following dexamethasone use for very low birth weight infants. Pediatric Research 2000;47:310A (Abstract 1832).
27. Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver RG, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birthweight infants. Pediatrics 1999;104:22-7.
28. Nixon PA, Washburn LK, Schechter MS, O'Shea TM. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. Journal of Pediatrics 2007;150:345-50.
29. O'Shea TM, Goldstein DJ, Jackson BG, Kothadia JM, Dillard RG. Randomized trial of a 42-day tapering course of dexamethasone in very low birth weight infants: neurological, medical and functional outcome at 5 years of age. Pediatric Research 2000;47:319A (abstract 1883).
30. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21.
31. Washburn LK, Nixon PA, O'Shea TM. Follow-up of a randomized, placebo-controlled trial of postnatal dexamethasone: blood pressure and anthropometric measurements at school age. Pediatrics 2006;118:1592-9.
32. Kovacs L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatrica 1998;87:792-8.
33. Kovacs LB. Personal communication. email 2002.
34. Noble-Jamieson CM, Regev R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. European Journal of Pediatrics 1989;148:365-7.
35. Ohlsson A. MSc Thesis. A randomized controlled trial of dexamethasone treatment in very low birthweight infants with ventilator dependent chronic lung disease. McMaster University 1990.
36. Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease. Acta Paediatrica 1992;81:751-6.
37. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. New England Journal of Medicine 1998;338:1112-8.
38. Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, et al. Dexamethasone therapy increases infection in low birth weight infants. Pediatrics 1999;104:e63.
39. Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Tyson JE. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. Journal of Pediatrics 2013;162(4):685-90.
40. Romagnoli C, Vento G, Tortorolo L, et al. Dexamethasone for the prevention of chronic lung disease in preterm neonates: a prospective randomized study [II desametazone nella prevenzione della patologia polmonare cronica del neonato pretermine: studio prospettico randomizzato]. Riv Italiano Pediatrics 1998;24:283-8.
41. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. A three year follow-up of preterm infants after moderately early treatment with dexamethasone. Archives of Disease of Childhood Fetal and Neonatal Edition 2002;87:F55-8.
42. Romagnoli C, Zecca E, Vento G, Maggio L, Papacci P, Tortorolo G. Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. Pharmacology 1999;59:266-74.
43. Scott SM, Backstrom C, Bessman S. Effect of five days of dexamethasone therapy on ventilator dependence and adrenocorticotropic hormone-stimulated cortisol concentrations. Journal of Perinatology 1997;17(1):24-8.
44. Vento G. Personal communication. email 2012.
45. Vento G, Matassa PG, Zecca E, Tortorolo L, Martelli M, De Carolis MP, et al. Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology 2004;71:113-9.
46. Vincer MJ. Personal communication. email 2002.
47. Vincer MJ, Allen AC. Double blind randomized controlled trial of 6-day pulse of dexamethasone for very low birth weight infants (VLBW <1500 grams) who are ventilator dependent at 4 weeks of age. Pediatric Research 1998;43:201A.
48. Walther F. Personal communication. email 2012.
49. Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. Early Human Development 2003;74:37-45.
50. Anttila E, Peltoniemi O, Haumont D, Herting E, ter Horst H, Heinonen K, et al. Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. European Journal of Pediatrics 2005;164(8):472-81. [PUBMED: 15864643]
51. Armstrong DL, Penrice J, Bloomfield FH, Knight DB, Dezoete JA, Harding JE. Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease. Archives of Disease of Childhood. Fetal and Neonatal Edition 2002;86:F102-7.
52. Ashton MR, Postle AD, Smith DE, Hall MA. Surfactant phosphadidylcholine composition during dexamethasone treatment in chronic lung disease. Archives of Disease of Childhood. Fetal and Neonatal Edition 1994;71:F114-7.
53. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW Jr, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972;50(4):526-34. [PUBMED: 4561296]
54. Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974;53(6):877-83.
55. Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Feasibility study of early blood pressure management in extremely preterm infants. Journal of Pediatrics 2012;161(1):65-9.e1. [PUBMED: 22336574]
56. Biswas S, Buffery J, Enoch H, Bland M, Markiewicz M, Walters D. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial--thyroid hormone replacement in neonates. Pediatric Research 2003;53(1):48-56. [PUBMED: 12508081]
57. Bloomfield FH, Knight DB, Harding JE. Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. Journal of Pediatrics 1998;133:395-400.
58. Bonsante F, Latorre G, Iacobelli S, Forziati V, Laforgia N, Esposito L, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007;91(4):217-21. [PUBMED: 17568152]
59. Couser RJ, Ferrara TB, Falde B, Johnson K, Schilling CG, Hoekstra RE. Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema. Journal of Pediatrics 1992;121:591-6.
60. Cranefield DJ, Odd DE, Harding JE, et al. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone. Pediatric Radiology 2004;34:1090-7.
61. Durand M, Mendoza MW, Tantivit P, Kugelman A, McEvoy C. A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation. Pediatrics 2002;109:262-8.
62. Efird MM, Heerens AT, Gordon PV, Bose CL, Young DA. A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. Journal of Perinatology 2005;25(2):119-24. [PUBMED: 15329742]
63. Ferrara TB, GeorgieffMK, Ebert TJ, Fisher JB. Routine use of dexamethasone for the prevention of post-extubation respiratory distress. Journal of Perinatology 1989;9:287-90.
64. Garland JS, Alex CP, Pauly TH, Whitehead VL, Brand J, Winston JF, et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics 1999;104(1 Pt 1):91-9. [PUBMED: 10390266]
65. Groneck P, Reuss D, Gotze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. Journal of Pediatrics 1993;122:938-44.
66. Halac E, Halac J, Begue EF, Casanas JM, Indiveri DR, Petit JF, et al. Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics 1990;117(1 Pt 1):132-8. [PUBMED: 2196355]
67. Kopelman AE, Moise AA, Holbert D, Hegemier SE. A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics 1999;135(3):345-50. [PUBMED: 10484801]
68. Lin YJ, Yeh TF, Hsieh WS, Chi YC, Lin HC, Lin CH. Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatric Pulmonology 1999;27(1):21-6. [PUBMED: 10023787]
69. Mammel MC, Green TP, Johnson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;i:1356-8.
70. Merz U, Peschgens T, Kusenbach G, Hörnchen H. Early versus late dexamethasone treatment in preterm infants at risk for chronic lung disease: a randomized pilot study. European Journal of Pediatrics 1999;158:318-22.
71. Mukhopadhyay K, Kumar P, Narang A. Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics 1998;35(2):117-22. [PUBMED: 9707853]
72. Ng PC, Lee CH, Bnur FL, Chan IH, Lee AW, Wong E, et al. A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 2006;117(2):367-75. [PUBMED: 16452355]
73. Odd DE, Armstrong DL, Teele RL, Kuschel CA, Harding JE. A randomized trial of two dexamethasone regimens to reduce side-effects in infants treated for chronic lung disease of prematurity. Journal of Paediatrics and Child Health 2004;40:282-9.
74. Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. Journal of Pediatrics 2005;146(5):632-7. [PUBMED: 15870666]
75. Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari MA, et al. Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology 2009;95(3):240-7.
76. Morales P, Rastogi A, Bez ML, Akintorin SM, Pyati S, Andes SM, et al. Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatric Cardiology 1998;19(3):225-9.
77. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996;98(2 Pt 1):204-10. [PUBMED: 8692619]
78. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics 2002;109(6):e85.
79. Romagnoli C, Zecca E, Vento G, De Carolis MP, Papacci P, Tortorolo G. Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Medicine 1999;25(7):717-21. [PUBMED: 10470576]
80. Romagnoli C, Zecca E, Vento G, Maggio L, Papacci P, Tortorolo G. Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. Pharmacology 1999;59:266-74.
81. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research 1994;36(1 Pt 1):122-8. [PUBMED: 7936832]
82. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition 2000;83(3):F177-81.
83. Shinwell ES, Karplus M, Reich D, et al. Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics in Neonatology. Ross Laboratories, 1999:240-54.
84. Shinwell ES, Karplus M, Zmora E, Reich D, Rothschild A, Blazer S, et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition 1996;74(1):F33-7. [PUBMED: 8653433]
85. D'Angio CT, Maniscalco WM, Ryan RM, Avissar NE, Basavegowda K, Sinkin RA. Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate 1999;76(5):266-73.
86. Sinkin RA, Dweck HS, Horgan MJ, Gallaher KJ, Cox C, Maniscalco WM, et al. Early dexamethasone-attempting to prevent chronic lung disease. Pediatrics 2000;105(3 Pt 1):542-8. [PUBMED: 10699107]
87. Soll RF for the Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research 1999;45:226A.
88. The Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics 2001;108(3):741-8.
89. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. New England Journal of Medicine 2001;344(2):95-101. [PUBMED: 11150359]
90. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, et al. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics 2013 Aug 27 [Epub ahead of print].
91. Subhedar NV, Bennett AJ, Wardle SP, Shaw NJ. More trials on early treatment with corticosteroids are needed. BMJ (Clinical research ed.) 2000;320(7239):947.
92. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 1997;77(3):F185-90. [PUBMED: 9462187]
93. Suske G, Oestreich K, Varnholt V, Lasch P, Kachel W. Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatrica 1996;85(6):713-8. [PUBMED: 8816210]
94. Tapia JL, Ramirez R, Cifuentes J, Fabres J, Hubner ME, Bancalari A, et al. The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. Journal of Pediatrics 1998;132(1):48-52. [PUBMED: 9469999]
95. Wang JY, Yeh TF, Lin YC, Miyamura K, Holmskov U, Reid KB. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax 1996;51(9):907-13. [PUBMED: 8984701]
96. Wang JY, Yeh TF, Lin YJ, Chen WY, Lin CH. Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatrics 1997;23(3):193-7.
97. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114(6):1649-57. [PUBMED: 15574629]
98. Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007;120(1):40-8.
99. Wilson DM, Baldwin RB, Ariagno RL. A randomized, placebo-controlled trial of effects of dexamethasone on hypothalmic-pituitary-adrenal axis in preterm infants. Journal of Pediatrics 1988;113:764-8.
100. Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. Journal of Pediatrics 1990;117(2 Pt 1):273-82. [PUBMED: 2199642]
101. Lin YJ, Lin CH, Wu JM, Tsai WH, Yeh TF. The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica 2005;94(3):310-6.
102. Lin YJ, Yeh TF, Lin HC, Wu JM, Lin CH, Yu CY. Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica 1998;87(10):1061-5.
103. Peng CT, Lin HC, Lin YJ, Tsai CH, Yeh TF. Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics 1999;104(3 Pt 1):476-81.
104. Yeh TF, Lin IJ, Hsieh WS, et al. Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy--A multicenter double-blind controlled study. Pediatric Research 1994;35:262A.
105. Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 1997;100(4):E3. [PUBMED: 9310536]
106. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;101(5):E7.
107. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine 2004;350(13):1304-13.
108. Yoder MC, Chua R, Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function in ventilator-dependent infants with bronchopulmonary dysplasia. American Reviews of Respiratory Disease 1991;143:1044-8.
109. Onland W, Offringa M, Cools F, Jaegere AP, Rademaker K, Blom H, et al. Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Paediatrics 2011;11:102.
110. Anonymous. Dexamethasone for neonatal chronic lung disease. Lancet 1991;338:982-3.
111. Ariagno RL, Sweeney TE, Baldwin RB, Inguillo D, Martin D. Controlled trial of dexamethasone in preterm infants at risk for bronchopulmonary dysplasia: lung function, clinical course and outcome at three years. Unpublished manuscript supplied by authors 2000.
112. Arias-Camison JM, Lau J, Cole CH, Frantz ID. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatric Pulmonology 1999;341:1190-6.
113. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Archives of Disease of Childhood. Fetal and Neonatal Edition 1998;79:F26-3.
114. Doyle LW, Davis PG. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. Journal of Paediatrics and Child Health 2000;36:101-7.
115. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 2007;119:716-21.
116. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(2):111-7.
117. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(3):217-24.
118. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(4):289-96.
119. Doyle LW, Ehrenkranz RE, Halliday HL. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD001146.pub4]
120. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997;100(1):E4. [http://www.pediatrics.org/egi/content/full/100/1/e4]
121. Flagel SB, Vazquez DM, Watson SJ Jr, Neal CR. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. American Journal of Regulatory Integrative Comparative Physiology 2002;282:R55-66.
122. Gibson AT, Pearse RG, Wales JKH. Growth retardation after dexamethasone administration: assessment by knemometry. Archives of Disease of Childhood 1993;69:505-9.
123. Giffin F, Greenough A. A pilot study assessing inhaled budesonide in chronically oxygen-dependent infants. Acta Paediatrica 1994;83:669-71.
124. Gramsbergen A, Mulder EJH. The influence of betamethasone and dexamethasone on motor development in young rats. Pediatric Research 1998;44:105-10.
125. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005;115:681-7.
126. Halliday HL. A review of postnatal corticosteroids for treatment and prevention of chronic lung disease in the preterm infant. Prenatal Neonatal Medicine 1997;2:1-2.
127. Halliday HL. Clinical trials of postnatal corticosteroids: Inhaled and systemic. Biology of the Neonate 1999;76(Suppl 1):29-40.
128. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
129. Hofkosh D, Brozanski BS, Edwards MD, et al. One year outcome of infants treated with pulse dexamethasone for prevention of BPD. Pediatric Research 1995;37:259A.
130. Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3 year follow-up. Pediatrics 1995;96:897-906.
131. Jones RA. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13-to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics 2005;116:370-8.
132. Jones RA. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13-to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. Pediatrics 2005;116:379-84.
133. La Force WR, Budno DS. Controlled trial of beclomethasone dipropionate by rehydration in oxygen-and ventilator-dependent infants. Journal of Pediatrics 1993;122:285-8.
134. Mieskonen S, Eronen M, Malmberg LP, Turpeinen M, Kari MA, Hallman M. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth. Acta Paediatrica 2003;92:896-904.
135. Ng PC. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Archives of Disease of Childhood 1993;68:330-6.
136. Nixon PA, Washburn LK, Schechter MS, O'Shea TM. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. Journal of Pediatrics 2007;150:345-50.
137. Northway WH, Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357-68.
138. Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD002311.pub2]
139. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
140. Torrioli G, Tortorolo G. A three year follow-up of preterm infants after moderately early treatment with dexamethasone. Archives of Disease of Childhood. Fetal and Neonatal Edition 2002;87:F55-8.
141. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD002058]
142. Shah V, Ohlsson A, Halliday H, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD001969.pub2]
143. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002057.pub2]
144. Stanley FJ. Using cerebral palsy data in the evaluation of neonatal intensive care: a warning. Developmental Medicine and Child Neurology 1982;24:93-4.
145. Tarnow-Mordi W. Postnatal dexamethasone in preterm infants. BMJ 1999;319:1385-6.
146. Tschanz SA, Damke BM, Burri PH. Influence of postnatally administered glucocorticoids on rat lung growth. Biology of the Neonate 1995;68:229-45.
147. Washburn LK, Nixon PA, O'Shea TM. Follow-up of a randomized, placebo-controlled trial of postnatal dexamethasone: blood pressure and anthropometric measurements at school age. Pediatrics 2006;118:1592-9.
148. Watterberg KL, Gerdes JS, Gifford KL, Lin H-M. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258-63.
149. Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurologic hazards. Annals of Neurology 1977;2:364-6.
150. Halliday HL. Postnatal corticosteroids in the preterm infants with chronic lung disease: Late treatment (>3 weeks). Cochrane Database of Systematic Reviews 1998, Issue 3. [DOI: 10.1002/14651858.CD001145]
151. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001144]
152. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001145]
153. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD001145]
154. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001144]
155. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001144]
156. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001145]
157. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001145.pub2]